There are described polypeptides which differ from lymphotoxin by lacking amino acids on the N-terminal end of the lymphotoxin. The polypeptides can be prepared by genetic engineering and are suitable as pharmaceuticals, either on their own or in combination with lymphokines and/or carcinostatics.